HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study

AIDS Research and Therapy

Amin S Hassan²  Helen M Nabwera²  Shalton M Mwaringa²  Clare A Obonyo⁵  Eduard J Sanders⁴  Tobias F Rinke de Wit³  Patricia A Cane¹  James A Berkley⁴ 

[1] Health Protection Agency, London, UK

[2] KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya

[3] Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

[4] Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford, Oxford, UK

[5] Kilifi District Hospital, Kilifi, Kenya

关键词: Kenya;    Rural;    Correlates;    Acquired drug resistance;    Virologic failure;    HIV;   

Others  :  789542
DOI  :  10.1186/1742-6405-11-9

 received in 2013-07-12, accepted in 2014-01-19,  发布年份 2014

【 摘 要 】

Background

An increasing number of people on antiretroviral therapy (ART) in sub-Saharan Africa has led to declines in HIV related morbidity and mortality. However, virologic failure (VF) and acquired drug resistance (ADR) may negatively affect these gains. This study describes the prevalence and correlates of HIV-1 VF and ADR among first-line ART experienced adults at a rural HIV clinic in Coastal Kenya.

Methods

HIV-infected adults on first-line ART for ≥6 months were cross-sectionally recruited between November 2008 and March 2011. The primary outcome was VF, defined as a one-off plasma viral load of ≥400 copies/ml. The secondary outcome was ADR, defined as the presence of resistance associated mutations. Logistic regression and Fishers exact test were used to describe correlates of VF and ADR respectively.

Results

Of the 232 eligible participants on ART over a median duration of 13.9 months, 57 (24.6% [95% CI: 19.2 – 30.6]) had VF. Fifty-five viraemic samples were successfully amplified and sequenced. Of these, 29 (52.7% [95% CI: 38.8 – 66.3]) had at least one ADR, with 25 samples having dual-class resistance mutations. The most prevalent ADR mutations were the M184V (n = 24), K103N/S (n = 14) and Y181C/Y/I/V (n = 8). Twenty-six of the 55 successfully amplified viraemic samples (47.3%) did not have any detectable resistance mutation. Younger age (15–34 vs. ≥35 years: adjusted odd ratios [95% CI], p-value: 0.3 [0.1–0.6], p = 0.002) and unsatisfactory adherence (<95% vs. ≥95%: 3.0 [1.5–6.5], p = 0.003) were strong correlates of VF. Younger age, unsatisfactory adherence and high viral load were also strong correlates of ADR.

Conclusions

High levels of VF and ADR were observed in younger patients and those with unsatisfactory adherence. Youth-friendly ART initiatives and strengthened adherence support should be prioritized in this Coastal Kenyan setting. To prevent unnecessary/premature switches, targeted HIV drug resistance testing for patients with confirmed VF should be considered.

【 授权许可】

   
2014 Hassan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]UNAIDS: Core slides: Global summary of the AIDS epidemic. 2012. Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_epi_core_en.pdf webcite]. Accessed 20 Nov 2012
• [2]UNAIDS: Global AIDS epidemic facts and figures. 2012. Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_FactSheet_Global_en.pdf webcite]. Accessed 20 Nov 2012
• [3]NACC and NASCOP: Kenya AIDS Epidemic update. 2012. Available at: [http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_KE_Narrative_Report.pdf webcite]. Accessed 04 April 2013
• [4]Bendavid E, Bhattacharya J: The president’s emergency plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med 2009, 150(10):688-695.
• [5]Jahn A, Floyd S, Crampin AC, et al.: Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008, 371(9624):1603-1611.
• [6]UNAIDS: World AIDS Day Report. 2011. Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf webcite]. Accessed 20 Nov 2012
• [7]Gupta RK, Hill A, Sawyer AW, et al.: Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9(7):409-417.
• [8]Keiser O, Tweya H, Boulle A, et al.: Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009, 23(14):1867-1874.
• [9]World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 rev. Available at: [http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf webcite]. Accessed 20 Nov 2012
• [10]Badri M, Lawn SD, Wood R: Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008, 8:89.
• [11]Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008, 22(15):1971-1977.
• [12]van Oosterhout JJ, Brown L, Weigel R, et al.: Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009, 14(8):856-861.
• [13]Barth RE, Tempelman HA, Moraba R, Hoepelman AI: Long-term outcome of an HIV-treatment programme in Rural Africa: viral suppression despite early mortality. AIDS Res Treat 2011, 2011:434375.
• [14]Kantor R, Diero L, Delong A, et al.: Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009, 49(3):454-462.
• [15]Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10(3):155-166.
• [16]Stadeli KM, Richman DD: Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013, 18(1):115-123.
• [17]National AIDS & STI Control Programme: Kenya National Clinical Manual For ART Providers. Available at: [http://nascop.or.ke/library/ART%20guidelines/Kenya%20clinical%20National%20Manual%20for%20ART%20providers.pdf webcite]. Accessed 20 Nov 2012
• [18]Hassan AS, Fielding KL, Thuo NM, et al.: Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study. Trop Med Int Health 2012, 17(1):82-93.
• [19]Goldman JD, Cantrell RA, Mulenga LB, et al.: Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24(8):1031-1035.
• [20]Weidle PJ, Wamai N, Solberg P, et al.: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368(9547):1587-1594.
• [21]Cane P: HIV drug resistance testing. Methods Mol Biol 2011, 665:123-132.
• [22]Liu TF, Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42(11):1608-1618.
• [23]Rhee SY, Gonzales MJ, Kantor R, et al.: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003, 31(1):298-303.
• [24]Kosakovsky Pond SL, Posada D, Stawiski E, et al.: An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol 2009, 5(11):e1000581.
• [25]National aIDS & STI Control Program: Guidelines for antiretroviral therapy in Kenya. 4th edition. 2011. [Available at: [http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Kenya%20Treatment%20Guidelines%202011.pdf webcite]. Accessed 04 May 2013
• [26]Stadeli KM, Richman DD: Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013, 18(1):115-123.
• [27]World Health Organization: HIV Drug Resistance Early Warning Indicators. World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update. Available at: [http://www2.paho.org/hq/dmdocuments/2010/hivdr-early-warning-indicators—updated-april-2010.pdf webcite]. Accessed 20 Nov 2012
• [28]Sigaloff KC, Hamers RL, Menke J, et al.: Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis 2012, 54(Suppl 4):S294-S299.
• [29]El-Khatib Z, Katzenstein D, Marrone G, et al.: Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One 2011, 6(3):e17518.
• [30]Nachega JB, Hislop M, Dowdy DW, et al.: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006, 43(1):78-84.
• [31]Messou E, Chaix ML, Gabillard D, et al.: Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d’Ivoire. J Acquir Immune Defic Syndr 2011, 56(4):356-364.
• [32]Dowshen N, D’Angelo L: Health care transition for youth living with HIV/AIDS. Pediatrics 2011, 128(4):762-771.
• [33]Assoumou L, Descamps D, Yerly S, et al.: Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother 2013, 68(6):1400-1405.
• [34]Nettles RE, Kieffer TL, Kwon P, et al.: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293(7):817-829.
• [35]Lee PK, Kieffer TL, Siliciano RF, Nettles RE: HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006, 57(5):803-805.
• [36]van Sighem A, Zhang S, Reiss P, et al.: Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48(1):104-108.
• [37]Hamers RL, Wallis CL, Kityo C, et al.: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011, 11(10):750-759.
• [38]Gupta RK, Jordan MR, Sultan BJ, et al.: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012, 380(9849):1250-1258.
• [39]Hamers RL, Schuurman R, Sigaloff KC, et al.: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012, 12(4):307-317.
• [40]Kuritzkes DR, Lalama CM, Ribaudo HJ, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008, 197(6):867-870.
• [41]Wittkop L, Gunthard HF, de Wolf F, et al.: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011, 11(5):363-371.
• [42]Hassan AS, Mwaringa SM, Obonyo CA, et al.: Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a Rural HIV clinic in Kenya. AIDS Res Hum Retroviruses 2013, 29(1):129-135.